Treatments & Interventions
Clinical Trials
Recent Trials
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan
Research Evidence
Peer-reviewed studies linked via MeSH term "Hypophosphatasias" from the MEDLINE/PubMed database.
Research data from MEDLINE/PubMed
Signs & Symptoms
Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.
Quick Facts
- SNOMED CT
- 360792001
- UMLS CUI
- C0020630
- Fully Specified Name
- Deficiency of alkaline phosphatase (disorder)
- Specialists
- 0
- Diagnostic Biomarkers
- 0
- HPO Phenotypes
- 20
- Known Treatments
- 1
- Clinical Trials
- 3
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.